Warren Buffett Comments on Valeant Pharma (VRX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/26/2026
- Wall St futures fall as chip stocks resume slide after Micron-led rally
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
- Needham Starts NeoVolta (NEOV) at Buy
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- SanDisk stock target lifted by Citi on continued demand strength
Valeant (VRX) 10-K Not Enough to Bring Back the Bulls or Scare The Bears - BMO Capital
May 2, 2016 9:56 AM EDTBMO Capital analyst Alex Arfaei reiterated a Market Perform rating and lowered his price target on Valeant Pharmaceuticals (NYSE: VRX) to $44.00 (from $66.00), saying the 10K is not enough to bring back the bulls or scare the bears.
Arfaei commented, "The good news was that we didnt find any new smoking guns in the 10-K. Valeant has averted technical default on its debt, and based on our... More
Valeant's (VRX) Debt Covenants Remain a Concern After 10K Filing - Piper Jaffray
May 2, 2016 7:43 AM EDTPiper Jaffray analyst, David Amsellem, noted that Valeant's (NYSE: VRX) 10K for 2015 contained one kernel of good news: it cured the default on its senior notes related to the late filing. Unfortunately that was "the only piece of good news". Here are the problems:
Wholesaler inventory... More
